➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Baxter
McKinsey
AstraZeneca

Last Updated: August 8, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Afuresertib

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Afuresertib?

Afuresertib is an investigational drug.

There have been 9 clinical trials for Afuresertib. The most recent clinical trial was a Phase 1 trial, which was initiated on June 9th 2020.

The most common disease conditions in clinical trials are Neoplasms, Plasma Cell, Multiple Myeloma, and Ovarian Neoplasms. The leading clinical trial sponsors are GlaxoSmithKline, Novartis Pharmaceuticals, and Laekna Limited.

There are thirteen US patents protecting this investigational drug and one hundred and seventy-seven international patents.

Recent Clinical Trials for Afuresertib
TitleSponsorPhase
Study With Afuresertib and Paclitaxel in Platinum Resistant OvarianLaekna LimitedPhase 2
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPCLaekna LimitedPhase 1/Phase 2
Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or AibrateroneGlaxoSmithKlinePhase 1

See all Afuresertib clinical trials

Clinical Trial Summary for Afuresertib

Top disease conditions for Afuresertib
Top clinical trial sponsors for Afuresertib

See all Afuresertib clinical trials

US Patents for Afuresertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Afuresertib   Start Trial Inhibitors of Akt activity GlaxoSmithKline LLC (Philadelphia, PA)   Start Trial
Afuresertib   Start Trial Inhibitors of Akt activity GlaxoSmithKline LLC (Philadelphia, PA)   Start Trial
Afuresertib   Start Trial Pharmaceutical composition GlaxoSmithKline LLC (Philadelphia, PA)   Start Trial
Afuresertib   Start Trial Chemical compounds GlaxoSmithKline LLC (Philadelphia, PA)   Start Trial
Afuresertib   Start Trial Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-m- ethyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride GlaxoSmithKline LLC (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Afuresertib

Drugname Country Document Number Estimated Expiration Related US Patent
Afuresertib Argentina 066184 2027-02-07   Start Trial
Afuresertib Australia 2008213694 2027-02-07   Start Trial
Afuresertib Brazil PI0807146 2027-02-07   Start Trial
Afuresertib Canada 2678255 2027-02-07   Start Trial
Afuresertib Chile 2008000348 2027-02-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Dow
Baxter
McKinsey
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.